Impact of COVID-19 on mental health research: is this the breaking point?

Accepted/In Press date: 21 December 2021

e-pub ahead of print date: 17 February 2022

Published date: 1 May 2022

Additional Information: Funding Information: K.B. is the Editor-in-Chief of the British Journal of Psychiatry. S.C. is funded by the Wellcome Trust, he has received honoraria from Elsevier and previously consulted for promentis. B.D. receives funding from the NIHR HTA programme. T.F. receives funding from UKRI to track the impact of COVID-19 on the mental health of children and young people and consults for Place2Be. N.H. is the chair of board of trustees of Manchester Global Foundation a Charitable Incorporated Organisation registered in England and Wales. He has received honorarium and travel grants from various pharmaceutical industries. He is an NIHR senior investigator. I.J. receives funding from Health and Care Research Wales to study the impact of COVID-19 on people with lived experience of mental illness. A.L.-H. is a Handling Editor of BJPsych and was the immediate past chair of the Academic Faculty of the Royal College of Psychiatrists; she has received research support and honoraria from Lundbeck, GSK and Alcarelle, paid consultancy to Silence and unpaid consultancy to AstraZeneca, Opiant, Britannia Pharmaceuticals outside the submitted work. R.S. has received support and honoraria from LivaNova, UCB, Eisai, Veriton Pharma, Bial, Averelle and GW pharmaceuticals outside the submitted work. L.S. Is funded by a Junior Fellowship from the Alzheimer's Society. J.S. has been principal investigator or chief investigator on studies sponsored by Takeda, Janssen and Lundbeck Plc. He has attended an Investigators’ meeting run by Allergan Plc. A.Y. is deputy Editor of BJPsych Open, has received payment for lectures or advisory work from: Astrazeneca, Eli Lilly, Lundbeck, Sunovion, Servier, LivaNova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS. Is a consultant to Johnson & Johnson and LivaNova. Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal investigator in the Restore-Life VNS registry study funded by LivaNova. Principal investigator on ESKETINTRD3004. Is the principal investigator on ‘The Effects of Psilocybin on Cognitive Function in Healthy Participants.’ Is principal investigator on ‘The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD).’ UK chief investigator for Novartis MDD study MIJ821A12201. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK). No shareholdings in pharmaceutical companies. W.L. is deputy editor of the British Journal of Psychiatry. A.B., R.D., S.F., H.K., C.M., J.R., A.S. and O.S. have no competing interests to declare. Publisher Copyright: Copyright © The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. Copyright: Copyright 2022 Elsevier B.V., All rights reserved.

Keywords: Education and training, clinical governance, cost-effectiveness, economics, supervision

Local EPrints ID: 456408

URI: http://eprints.soton.ac.uk/id/eprint/456408

DOI: doi:10.1192/bjp.2022.8

ISSN: 0007-1250

PURE UUID: 63a2fe94-df1b-45e2-9ea5-87ea17f03e16

ORCID for Samuel Chamberlain: orcid.org/0000-0001-7014-8121

Date deposited: 28 Apr 2022 16:33

Last modified: 17 Mar 2024 04:03